Breaking News
May 22, 2018 - CSIRO study urges Australians to avoid junk protein foods for healthy weight loss
May 22, 2018 - Breath Test Shows Promise for Diagnosis of Esophagogastric CA
May 22, 2018 - Common class of drugs linked to dementia even when taken 20 years before diagnosis
May 22, 2018 - Optimal Biomarker Frequency for Biosensors
May 22, 2018 - Ethics of conducting clinical research during public health emergencies
May 22, 2018 - FDA Approves Aimovig (erenumab), The First Drug Aimed at Preventing Migraines
May 22, 2018 - Warning labels on alcohol containers highly deficient, new research shows
May 22, 2018 - Doctors publish comprehensive proposal to ensure universal access to safe, affordable medications
May 22, 2018 - When is insurance not really insurance? When you need pricey dental care.
May 22, 2018 - Thyroid tumors may be more susceptible to precisely targeted radiation treatment, suggests study
May 22, 2018 - Researchers uncover clues to early lung transplant failure
May 22, 2018 - Coagulation Factor Tests: MedlinePlus Lab Test Information
May 22, 2018 - Booze ads cause risky drinking in young people
May 22, 2018 - Are you and your primary care doc ready to talk about your DNA?
May 22, 2018 - UCI research team uncovers new unexpected mode of neurotransmitter-based communication
May 22, 2018 - Researcher develops nanoparticle-based tags to detect viruses and cancer with high sensitivity
May 22, 2018 - Researchers highlight need for transgender-inclusive healthcare providers
May 22, 2018 - Celgene to share new and updated data around novel hematological therapies
May 22, 2018 - Scientists identify cell types underlying schizophrenia
May 22, 2018 - ACR urges legislative action on access and cost barriers in rheumatologic care
May 22, 2018 - Study examines link between nicotine dependence and likelihood to quit smoking after lung cancer screening
May 22, 2018 - New report highlights danger of childhood drowning in open water
May 22, 2018 - Proposed definition of patient-centeredness and engagement in healthcare
May 22, 2018 - Scientists reveal likely cause of childhood leukaemia
May 22, 2018 - Specific patterns of fat distribution linked to metabolic disease, shows study
May 22, 2018 - Novel drug prevents memory impairment in mice exposed to simulated deep space radiation
May 22, 2018 - New LIVE scoring tool effectively predicts future risk of hospitalization for COPD patients
May 22, 2018 - Most people with preclinical signs of Alzheimer’s disease may not develop dementia
May 22, 2018 - Fetal MRI can accurately identify holoprosencephaly by 18 weeks of gestation
May 22, 2018 - Multidisciplinary clinic can provide quality care for low-income patients with lung conditions
May 22, 2018 - Researchers create tool to determine patient’s response to immunotherapy drugs
May 22, 2018 - Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers
May 22, 2018 - New technique allows researchers to control heart cells growing in a dish
May 22, 2018 - FDA Approves Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalemia
May 22, 2018 - Making America’s doctors look more like America
May 22, 2018 - Few parents use simple strategies to protect kids from food poisoning, reports study
May 22, 2018 - Reduction in heart disease risk factors could help prevent frailty among older adults
May 22, 2018 - Study finds age-related racial disparities in youth suicide
May 22, 2018 - Childhood leukemia linked to lack of childhood infections
May 22, 2018 - Scientists identify new drug target to combat chikungunya virus
May 22, 2018 - PSCK9 inhibitors may provide benefit to atherosclerosis patients with high lipoprotein(a) levels
May 22, 2018 - Celltrion Healthcare advocates early introduction of biologics for patients to improve clinical outcomes
May 22, 2018 - Local anesthetic drug not linked to reduction in opioid use, complications after knee surgery
May 22, 2018 - FDA Alert: Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement
May 22, 2018 - Post-surgical opioids can, paradoxically, lead to chronic pain
May 22, 2018 - Flow of cerebrospinal fluid found to be key signal for neural stem cell renewal
May 22, 2018 - Nipah virus kills nine in Kerala, India
May 22, 2018 - Higher body temperatures speed the bodies’ responses to infections and tumors, finds research
May 22, 2018 - Staying up all night, sleeping all day can swiftly impact over 100 proteins in the blood
May 22, 2018 - Combination of vascular risk and brain amyloid levels may accelerate age-related cognitive decline
May 22, 2018 - ASCO: Few Eligible Smokers Had CT Screen for Lung CA in 2016
May 22, 2018 - In Brazil, patients risk everything for the ‘right to beauty’
May 22, 2018 - Women with gestational diabetes may be at greater risk for chronic kidney disease
May 22, 2018 - Flavonoid intake may reduce lung function decline that occurs with aging
May 22, 2018 - AACN brings together over thousands of nurses for annual conference
May 22, 2018 - AHA: ‘Ideal’ Heart Health Eludes More Americans
May 22, 2018 - Drug used to treat daytime sleepiness does not appear to improve driving in those with sleep apnea
May 22, 2018 - Incorporation of AI could transform cancer diagnosis in UK
May 22, 2018 - Neurological protein found to protect against inflammatory diseases
May 22, 2018 - Lipoprotein (a) Blood Test: MedlinePlus Lab Test Information
May 22, 2018 - A new molecular target identified in depression
May 22, 2018 - Researchers discover new gene locations that determine heart’s response to exercise
May 21, 2018 - HCM mutation prevents the heart from increasing pumping force, study shows
May 21, 2018 - Intelligent brains possess fewer neuronal connections, finds study
May 21, 2018 - UA physicians developing new tool to detect urethral blockage
May 21, 2018 - Fish-eating habits of pregnant women not linked to autistic traits in their children
May 21, 2018 - Shingrix Shingles Vaccination | What You Should Know
May 21, 2018 - Early depression diagnosis is deadly serious for patients with coronary artery disease
May 21, 2018 - Reducing exposure to hormone interfering chemicals may mitigate obesity risk
May 21, 2018 - Analysis of lymph node dissection shows no overall survival benefit in renal carcinoma patients
May 21, 2018 - FDA Approves Aimovig (erenumab-aooe) as a Preventive Treatment for Migraine
May 21, 2018 - Infant death study reveals dangerous sleep practices among babysitters, relatives, others
May 21, 2018 - Intermittent fasting may increase diabetes risk, shows study
May 21, 2018 - Increase in local temperature correlates with higher degree of antibiotic resistance, finds study
May 21, 2018 - Treg infusions show promise in slowing progression of ALS
May 21, 2018 - New study shows declines in prostate cancer screening, diagnoses and treatment
May 21, 2018 - Fasting diets could raise risk of diabetes say experts
May 21, 2018 - FDA Alert: 7K and Poseidon 4500 by Shoreside Enterprises: Voluntary Recall
May 21, 2018 - Cell phones at summer camp: Research explores the effects
May 21, 2018 - Birth rate decline driven by waiting longer to have children, cost of infertility treatment
UAB-led clinical trial intends to find innovative treatment for multiple myeloma patients

UAB-led clinical trial intends to find innovative treatment for multiple myeloma patients

image_pdfDownload PDFimage_print

Multiple myeloma is the second most common type of blood cancer in the United States, impacting more than 25,000 people each year and disproportionatly affecting African-American men. While patients have access to more quality treatment therapies than ever before, the disease is still regarded as an incurable condition that often leads to death for those affected.

However, researchers at the University of Alabama at Birmingham Division of Hematology and Oncology are leading and currently recruiting for a Phase II clinical trial that intends to provide newly diagonosed multiple myeloma patients an innovative treatment plan. The hope is that the therapies will eradicate the disease in a significant proportion of patients and measure disease response more accurately than ever before.

The clinical trial Monoclonal Antibody Sequential Therapy for Deep Remission in Multiple Myeloma, also known as MASTER, utilizes next generation sequencing technology to detect minimal residual disease down to a level of one cancer cell in 100,000 -; or 100- to 1,000-fold more sensitive than traditional methods to evaluate response. With a goal of enrolling 82 patients, those in the trial will be treated with a combination of anti-myeloma agents and immunotherapy that have a proven record of eliminating minimal residual disease, including the drug carfilzomib and the monoclonal antibody daratumumab, agents that are currently only approved to treat patients whose disease has returned.

“I believe for the first time that we have treatments that are effective enough to make it possible to eradicate multiple myeloma definitively in a substantial proportion of patients, along with having the technology to detect that the disease has been targeted and that treatment can be stopped,” said Luciano Costa, M.D., Ph.D., scientist at the UAB Comprehensive Cancer Center, lead of the Hematologic-Malignancy Working Group, and principal investigator of the MASTER study. “That is what patients want, after all -; a treatment that gives them the possibility of eliminating any trace of the myeloma without having to be on therapy for the rest of their lives. It is a bold move, but bold moves are what our patients deserve.”

Multiple myeloma is the second most common type of blood cancer in the U.S., impacting more than 25,000 people each year and disproportionatly affecting African-American men.

This is one of the first trials in multiple myeloma to use minimal residual disease as primary endpoint and the very first one to modify therapy based on achievement of minimal residual disease eradication.

Up until now, existing therapies have been developed on trials that assigned treatment for a defined duration of time, irrespective of depth or speed of response, often followed by maintenance therapy for indefinite duration and with potentially adverse impact on risk of complications and cost. As it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.

More than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy. Patients will be monitored for relapse at the molecular level, before disease becomes again symptomatic.

Source:

https://uab.edu/news/research/item/9429-uab-recruiting-for-clinical-trial-to-determine-therapies-for-eradication-of-multiple-myeloma

Tagged with:

About author

Related Articles